More about

Ace Inhibitor

News
June 13, 2020
3 min read
Save

Aggressive management in stage 3 CKD preserves kidney function in diabetes

Aggressive management in stage 3 CKD preserves kidney function in diabetes

Adults with type 2 diabetes and a low estimated glomerular filtration rate must be more aggressively managed with tailored treatment options to preserve kidney function and reduce morbidity and mortality risk.

News
May 20, 2020
2 min read
Save

Some CV medications prescribed less often to women than men

Some CV medications prescribed less often to women than men

Women with established CVD had lower rates of prescriptions for statins, aspirin and ACE inhibitors compared with men, according to a systematic review and meta-analysis published in the Journal of the American Heart Association.

News
May 19, 2020
5 min read
Save

Evidence suggests no COVID-19-related harm from RAAS antagonists

Evidence suggests no COVID-19-related harm from RAAS antagonists

Because the virus that causes COVID-19 acts through the ACE2 receptor, there was concern that use of renin-angiotensin-aldosterone system antagonists might predispose people to COVID-19 or worsen its effects. But emerging data suggest that concern is unfounded.

News
May 15, 2020
2 min read
Save

Medicaid expansion improves HF therapy administration for certain racial/ethnic groups

Medicaid expansion improves HF therapy administration for certain racial/ethnic groups

The Affordable Care Act Medicaid Expansion increased receipt of ACE inhibitors, angiotensin II receptor antagonists and angiotensin receptor-neprilysin inhibitors for Hispanic patients hospitalized for HF, according to data presented at the virtual American Heart Association Quality of Care and Outcomes Research Scientific Sessions.

News
May 04, 2020
1 min read
Save

Top stories in cardiology: New trials to further assess hydroxychloroquine, safety of BP medications in COVID-19

A new study led by the Henry Ford Health System in Detroit will evaluate whether hydroxychloroquine can prevent COVID-19 in health care workers and first responders. This was the top story in cardiology last week.

News
May 01, 2020
6 min read
Save

Randomized trial underway to assess RAAS inhibitors in COVID-19

Randomized trial underway to assess RAAS inhibitors in COVID-19

Many international medical societies have endorsed the continuation of renin-angiotensin-aldosterone system inhibitors such as ACE inhibitors and angiotensin II receptor antagonists to control BP in patients during the COVID-19 pandemic despite concerns about the drugs’ relationship to ACE2, the receptor that helps the virus bind to cells. Researchers at the University of Pennsylvania Perelman School of Medicine recently started the REPLACE COVID trial to provide more information about the effects of these medications in patients hospitalized with COVID-19.

News
April 13, 2020
4 min read
Save

Endocrine-related targets may drive treatments for COVID-19

Endocrine-related targets may drive treatments for COVID-19

Available data assessing the COVID-19 pandemic indicate that case fatality rates are higher among men compared with women, and this distinction becomes more pronounced with advancing age. Little evidence supports theories that a higher prevalence of smoking among men or immune factors can explain the higher death rate among men.

News
March 23, 2020
1 min read
Save

Top stories in cardiology: Societies dispel misinformation about COVID-19, low BP in elderly confers mortality risk

Top stories in cardiology: Societies dispel misinformation about COVID-19, low BP in elderly confers mortality risk

Misinformation regarding the associations between the use of ACE inhibitors and angiotensin receptor blockers and an increased risk for COVID-19 have been addressed by several American and European cardiology societies. It was the top story in cardiology last week.

News
March 17, 2020
4 min read
Save

Cardiology societies recommend patients taking ACE inhibitors, ARBs who contract COVID-19 should continue treatment

Cardiology societies recommend patients taking ACE inhibitors, ARBs who contract COVID-19 should continue treatment

Several American and European cardiology societies issued statements to dispel misinformation circulating about an association between treatment with renin-angiotensin-aldosterone system antagonists such as ACE inhibitors and angiotensin receptor blockers and increased risk for COVID-19 and increased severity of the disease for those who have contracted COVID-19.

News
December 11, 2019
1 min read
Save

LEGEND-HTN

LEGEND-HTN

Safety and effectiveness of common antihypertensive treatments.

View more